Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Use of direct oral anticoagulants in clinical practice ; Uso de los anticoagulantes orales directos en la práctica clínica

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • بيانات النشر:
      Universidad Nacional de Colombia - Sede Bogotá - Facultad de Medicina
    • الموضوع:
      2016
    • Collection:
      Universidad Nacional de Colombia: Portal de Revistas UN
    • نبذة مختصرة :
      Direct oral anticoagulants arose in response to the search for an ideal anticoagulant, after warfarin was, for a long time, the only available oral anticoagulant. Factor Xa inhibitors —rivaroxaban and apixaban— and thrombin inhibitor —dabigatran etexilate— are already approved in Colombia. These pharmacological sets are warranted for thromboprophylaxis after hip and knee arthroplasty, prevention of stroke and systemic embolism in patients with atrial fibrillation and in the treatment of venous thromboembolism. The approval of these medicines came after showing their efficacy and safety compared with warfarin and enoxaparin. Some of the advantages offered by them include: rapid onset of action; predictable effect, low interindividual variability that eliminates the necessity of frequent monitoring; and fewer drug interactions. Somehow, similar to warfarin, bleeding is the major adverse event.The objective of this review is to acknowledge pharmacology of the direct oral anticoagulants, results of clinical trials supporting its use, dosage, perioperative management and switching between anticoagulants; conditions that create specific scenarios for each one of these drugs. ; Los anticoagulantes orales directos surgieron en respuesta a la búsqueda de un anticoagulante ideal después de que la warfarina fuera por mucho tiempo el único disponible. Los inhibidores del factor X activado —rivaroxabán y apixabán— y el inhibidor de trombina —dabigatrán etexilato— ya están aprobados en Colombia. Estos grupos farmacológicos están indicados en la tromboprofilaxis luego de artroplastia de rodilla y cadera, en la prevención del accidente cerebrovascular y el embolismo sistémico en pacientes con fibrilación auricular no valvular y en el tratamiento del tromboembolismo venoso. La aprobación de los inhibidores se dio luego de mostrar eficacia y seguridad al compararse con warfarina y enoxaparina. Entre las ventajas que estos presentan figuran las siguientes: inicio rápido de acción, efecto predecible, poca variabilidad ...
    • File Description:
      application/pdf; text/html
    • Relation:
      https://revistas.unal.edu.co/index.php/revfacmed/article/view/49963/56502; https://revistas.unal.edu.co/index.php/revfacmed/article/view/49963/56503; Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1995;108(4 Suppl):231S-46. http://doi.org/dgw8fp.; Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J. Manag. Care Pharm. 2009;15(3):244-52. http://doi.org/bc7z.; Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):204S-33. http://doi.org/bpbzd5.; Eikelboom JW, Weitz JI. New Anticoagulants. Circulation. 2010;121(13):1523-32. http://doi.org/dzfbf2.; Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart. 2012;98(7):573-8. http://doi.org/bc72.; Janzic A, Kos M. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control. Pharmacoeconomics. 2015;33(4):395-408. http://doi.org/bc73.; Ansell J. Warfarin versus new agents: interpreting the data. ASH Education Book. 2010;2010(1):221-8. http://doi.org/b723qp.; Gomez-Outes A, Suarez-Gea ML, Lecumberri R, Terleira-Fernandez AI, Vargas-Castrillon E. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat. Cardiovasc Drug Discov. 2014;9(1):2-10. http://doi.org/bc74.; Eby C. Novel anticoagulants and laboratory testing. Int. J. Lab. Hematol. 2013;35(3):262-8. http://doi.org/bc79.; Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin. Pharmacokinet. 2013;52(2):69-82. http://doi.org/bc8b.; Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J. Thromb. Haemost. 2008;6(5):820-9. http://doi.org/bsn8xp.; Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 -an oral, direct Factor Xa inhibitor- after multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol. 2005;61(12):873-80. http://doi.org/fh6ch5.; Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb. Haemost. 2010;104(6):1263-71. http://doi.org/d7jj8r.; Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat. Rev. Drug. Discov. 2011;10(1):61-75. http://doi.org/d74nsh.; Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br. J. Clin. Pharmacol. 2010;70(5):703-12. http://doi.org/ffh6p8.; Kubitza D, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H, et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br. J. Clin. Pharmacol. 2013;76(1):89-98. http://doi.org/bc8n.; Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J. Clin. Pharmacol. 2007;47(2):218-26. http://doi.org/cgqbf4.; Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (Rivaroxaban), an oral, direct factor xa inhibitor, in healthy subjects. J. Clin. Pharmacol. 2006;46(5):549-58. http://doi.org/bbrk4c.; Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15(5):625-51. http://doi.org/f234cw.; Indications and Usage for Warfarin. New Zealand: Drugs.com; 2016 [Revised 2016 Jan; cited 2016 Mar 11]; Available from: http://goo.gl/mbJ382.; Haas S. Prevention of venous thromboembolism: recommendations based on the International Consensus and the American College of Chest Physicians Sixth Consensus Conference on Antithrombotic Therapy. Clin. Appl. Thromb. Hemost. 2001;7(3):171-7. http://doi.org/cf43ph.; Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 2008;358(26):2765-75. http://doi.org/bkm8mt.; Kakkar AK, Brenner B, Dahl OE, Eriksson B, Mouret P, Muntz J, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31-9. http://doi.org/dg52wj.; Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 2008;358(26):2776-86. http://doi.org/dwdp27.; Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676):1673-80. http://doi.org/cdsrcj.; Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, et al. Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. N. Engl. J. Med. 2013;368(6):513-23. http://doi.org/f25mj5.; January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol. 2014;64(21):e1-76. http://doi.org/f2wfv9.; Connolly SJ, Eikelboom J, Joyner C, Diener H, Hart R, Golitsyn S, et al. Apixaban in Patients with Atrial Fibrillation. N. Engl. J. Med. 2011;364(9):806-17. http://doi.org/cfxgb3.; Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-72. http://doi.org/c43wcq.; Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N. Engl. J. Med. 2011;365(10):883-91. http://doi.org/bbcf6w.; Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur. Heart J. 2011;32(19):2387-94. http://doi.org/b9t9x9.; Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e152S-84S. http://doi.org/bc84.; Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. N. Engl. J. Med. 2010;363(26):2499-510. http://doi.org/dg8w5c.; Büller HR, Prins MH, Lensing AW, Decousus H, Jacobson BF, Minar E, et al. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N. Engl. J. Med. 2012;366(14):1287-97. http://doi.org/bc9m.; Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al. Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans. Drug Metab. Dispos. 2009;37(1):74-81. http://doi.org/c6gn5w.; He K, Luettgen JM, Zhang D, He B, Grace JE, Xin B, et al. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur. J. Drug Metab. Pharmacokinet. 2011;36(3):129-39. http://doi.org/d4gvmj.; Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, et al. Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. Clin. Pharmacol. 2013;5:177-84. http://doi.org/bc9n.; Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement. N. Engl. J. Med. 2009;361(6):594-604. http://doi.org/bvmcdd.; Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807-15. http://doi.org/dkf9mv.; Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement. N. Engl. J. Med. 2010;363(26):2487-98. http://doi.org/bsrbms.; Imberti D, Gallerani M, Manfredini R. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. J. Thromb Thrombolysis. 2012;34(2):208-13. http://doi.org/bc9p.; Nieto JA, Espada NG, Merino RG, González TC. Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: Pool-analysis of phase III randomized clinical trials. Thromb. Res. 2012;130(2):183-91. http://doi.org/bc9q.; Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, et al. Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients. N. Engl. J. Med. 2011;365(23):2167-77. http://doi.org/drz3x9.; Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N. Engl. J. Med. 2011;365(11):981-92. http://doi.org/d937xk.; Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. N. Engl. J. Med. 2013;369(9):799-808. http://doi.org/9v4.; Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for Extended Treatment of Venous Thromboembolism. N. Engl. J. Med. 2013;368(8):699-708. http://doi.org/bc9r.; Frost CE, Byon W, Song Y, Wang J, Schuster AE, Boyd RA, et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br. J. Clin. Pharmacol. 2015;79(5):838-46. http://doi.org/bc9s.; Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors. J. Med. Chem. 2002;45(9):1757-66. http://doi.org/bn7x5t.; Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin. Pharmacokinet. 2008;47(5):285-95. http://doi.org/c2h9pv.; Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br. J. Clin. Pharmacol. 2007;64(3):292-303. http://doi.org/d2jz5r.; Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J. Clin. Pharmacol. 2005;45(5):555-63. http://doi.org/dkrgb7.; Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin. Pharmacokinet. 2008;47(1):47-59. http://doi.org/ct8tqg.; Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386-99. http://doi.org/ftn3tm.; Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J. Clin. Pharmacol. 2008;48(12):1411-9. http://doi.org/cxm6f6.; Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin. Pharmacokinet. 2010;49(4):259-68. http://doi.org/dr3hrp.; Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949-56. http://doi.org/dfq32v.; Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011;105(4):721-9. http://doi.org/cqgs9j.; Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J. Thromb Haemost. 2007;5(11):2178-85. http://doi.org/bjprbt.; Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J. Arthroplasty. 2009;24(1):1-9. http://doi.org/bvjm86.; Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Perekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009;361(12):1139-51. http://doi.org/bcqddq.; Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 2009;361(24):2342-52. http://doi.org/dsm8kh.; Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc. Biol. 2010;30(10):1885-9. http://doi.org/cpnzdb.; Härtter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa(®) after co-medication with verapamil in healthy subjects. Br. J. Clin. Pharmacol. 2013;75(4):1053-62. http://doi.org/bc9t.; Delavenne X, Ollier E, Basset T, Bertoletti L, Accassat S, Garcin A, et al. A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Br. J. Clin. Pharmacol. 2013;76(1):107-13. http://doi.org/bc9v.; Härtter S, Koenen-Bergmann M, Sharma A, Nehmiz G, Lemke U, Timmer W, et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br. J. Clin. Pharmacol. 2012;74(3):490-500. http://doi.org/bc9w.; Härtter S, Sennewald R, Schepers C, Baumann S, Fritsch H, Friedman J. Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. Eur. J. Clin. Pharmacol. 2013;69(3):327-39. http://doi.org/bc9x.; Consulta datos de productos. Bogotá, D.C.: INVIMA; 2015 [cited 2015 Jan 3]; Available from: http://goo.gl/GOHQAn.; Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e152S-84. http://doi.org/bc84.; Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur. Heart J. 2014;35(43):3033-69. http://doi.org/9vr.; Janssen Pharmaceuticals Inc. Xarelto® Full prescribing information. 2014 [cited 2015 Jan 3]; Available from: http://goo.gl/dHjhrM.; Bristol-Myers Squibb Company, Pfizer Inc. Eliquis® Full prescribing information. 2014 [cited 2015 Jan 3]; Available from: http://goo.gl/tXlKq8.; Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa® Full prescribing information. 2012 [cited 2015 Jan 3]; Available from: http://goo.gl/53e3CI.; Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125(5):669-76. http://doi.org/fzc369.; Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjøth F, Rosenzweig M, Lane DA, et al. Myocardial Ischemic Events in 'Real World' Patients with Atrial Fibrillation Treated with Dabigatran or Warfarin. Am. J. Med. 2014;127(4):329-36.e4. http://doi.org/f2wz7q.; Douxfils J, Buckinx F, Mullier F, Minet V, Rabenda V, Reginster JY, et al. Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J. Am. Heart Assoc. 2014;3(3):e000515. http://doi.org/bc9z.; Hohnloser SH, Lip GY. DAbigatran and myocardial infarction. Chest. 2015;147(2):e70-1. http://doi.org/bc92.; Davidson BL. THe association of direct thrombin inhibitor anticoagulants with cardiac thromboses. Chest. 2015;147(1):21-4. http://doi.org/bc93.; Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, et al. 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(24):e278-333. http://doi.org/bc94.; Lai A, Davidson N, Galloway SW, Thachil J. Perioperative management of patients on new oral anticoagulants. Br. J. Surg. 2014;101(7):742-9. http://doi.org/bc95.; https://revistas.unal.edu.co/index.php/revfacmed/article/view/49963
    • Rights:
      Derechos de autor 2015 Revista de la Facultad de Medicina ; http://creativecommons.org/licenses/by/3.0/
    • الرقم المعرف:
      edsbas.B46EE3C